According to a study published in the Journal of Asthma and Allergy by researchers C.-T. Hung, C.-Y. An, C.-W. Suk, T.-W. Lee, and S.-H. Hung, adult patients with asthma and type 2 diabetes who use tirzepatide experience a similar risk of asthma exacerbations over a 12-month period compared to those using semaglutide. The retrospective cohort … Read more
A patient who used an unapproved peptide labelled as the weight-loss drug retatrutide suffered a potentially fatal torn oesophagus after experiencing uncontrollable vomiting, according to a warning issued by the Therapeutic Goods Administration (TGA). Laboratory testing revealed the product contained no retatrutide, but instead held an exceptionally high dose of undeclared semaglutide. TGA Warning Over … Read more
Millions of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity face renewed clarity regarding psychiatric safety, according to a systematic review published in the journal Cureus by Quadir et al. Researchers evaluating 11 primary studies representing over 4.9 million patients found no consistent class-wide increase in neuropsychiatric risks such as … Read more
According to researchers at Wuhan University, more than 3 billion people worldwide currently suffer from obesity, a figure forecasted to exceed 4 billion by 2035. To combat weight rebound and inflammation-suppressed fat browning linked to single-agent therapies, scientists developed an adipose-targeted composite microneedle patch named LRSG-SG@MN, which co-delivers semaglutide and rosiglitazone to modulate immune response … Read more
New research suggests that the cardiovascular health benefits of semaglutide may be more closely tied to the drug’s dosage than to the amount of weight a patient loses. A retrospective study published in npj Cardiovascular Health found that patients reaching higher maximum doses of semaglutide—1.7 mg or greater—experienced significantly lower risks of heart failure, cerebrovascular … Read more
The FDA’s approval of the Wegovy oral semaglutide pill in late December 2025 offers a needle-free weight management option, though it requires more rigorous dosing than the injectable version. According to Dr. Anthony Puopolo, Chief Medical Officer at LifeMD, the pill delivers the same molecule as the shot but faces biological barriers that demand strict … Read more
Nearly 4 in 10 patients with type 2 diabetes stop their GLP-1 medication within the first year of treatment, according to research presented at the Endocrine Society’s annual meeting, ENDO 2026. While discontinuation rates climb to nearly 6 in 10 by the end of two years, the data reveals a high frequency of patients restarting … Read more
GLP-1 receptor agonist medications, such as Ozempic and Wegovy, are associated with significantly lower rates of substance use disorders among patients with type 2 diabetes or obesity. A study published in Frontiers in Psychiatry found that patients taking these drugs showed reduced odds of alcohol, opioid, nicotine, and cocaine use disorders compared to similar patients … Read more
Research published in the journal Annals of Oncology indicates that GLP-1 receptor agonists (GLP-1 RAs) are associated with a 41% reduction in overall cancer risk among obese, non-diabetic adults. This study of more than 229,000 patients suggests these medications may offer significant benefits for cancer prevention beyond simple weight management. Which cancers are linked to … Read more
For years, the gold standard for medical knowledge has been the randomized controlled trial (RCT). While these trials are essential, they often exist in a “perfect” environment that doesn’t always mirror the messy, complex reality of daily clinical practice. That is changing. As presented at the latest EULAR Congress, the integration of real-world evidence (RWE) … Read more